Growth Hormone Stimulation Test: Medication-Driven Changes Explained

Why Medications Change Growth Hormone Stimulation Test Results

Medications alter GH stim results by acting on the hypothalamic-pituitary axis at multiple points: suppressing GHRH release, blocking somatotroph responsiveness, or modifying peripheral feedback loops. A result cannot be interpreted in isolation. The Endocrine Society's 2011 Clinical Practice Guideline on adult GH deficiency explicitly states that "medications known to affect GH secretion should be discontinued before testing when feasible." [1]

How the GH Axis Works in Brief

The pituitary somatotrophs release GH in pulses driven by hypothalamic GHRH and inhibited by somatostatin. Stimulation tests bypass normal pulsatility by pharmacologically forcing a GH surge. Insulin-induced hypoglycemia (the insulin tolerance test, ITT), GHRH combined with arginine, and glucagon are the three most commonly used provocative agents in adults. [1]

Any drug that tonically raises somatostatin tone, reduces GHRH amplitude, or blunts the counter-regulatory response to hypoglycemia will artificially lower the measured GH peak, potentially pushing a patient with borderline function below the diagnostic threshold.

The Diagnostic Cutoffs That Medications Can Push You Across

The Endocrine Society places the adult GH deficiency cutoff at a peak GH of <3 ng/mL on the ITT or the GHRH-arginine test in patients with a normal BMI. Because obesity independently suppresses GH secretion, the GHRH-arginine cutoff drops to <4 ng/mL at BMI >30 kg/m², and the glucagon stimulation test cutoff is <3 ng/mL overall. [1] A drug that reduces peak GH by even 1-2 ng/mL in someone whose true peak sits at 4-5 ng/mL can manufacture a false-positive diagnosis of GH deficiency.

Glucocorticoids and GH Suppression

Glucocorticoids are among the most potent suppressors of GH secretion clinically encountered. Both endogenous hypercortisolism (Cushing syndrome) and exogenous glucocorticoid therapy reduce spontaneous GH pulse amplitude and blunt stimulated GH release. [2]

Mechanism

Cortisol and synthetic glucocorticoids increase hypothalamic somatostatin tone and reduce somatotroph sensitivity to GHRH. In patients on chronic prednisone or dexamethasone, mean 24-hour GH secretion may fall by 40-60% compared with matched controls. [2]

Clinical Recommendation

If testing cannot be deferred, the clinician should document the glucocorticoid dose and timing, hold the morning dose on the day of testing when medically safe, and apply a low interpretive threshold. The Endocrine Society guideline notes that GH deficiency diagnosis should be deferred until after resolution or treatment of hypercortisolism whenever possible. [1]

Inhaled Steroids

High-dose inhaled corticosteroids used for asthma (e.g., fluticasone 500-1,000 mcg/day) produce measurable HPA-axis suppression and may modestly reduce GH stim peaks. The magnitude is smaller than oral glucocorticoids but clinically relevant in borderline cases. One pediatric study found peak GH responses reduced by approximately 15% in children on high-dose inhaled fluticasone compared with untreated controls. [3]

Sex Steroids: Priming, Suppression, and Route of Administration

Sex steroids have a complex, route-dependent relationship with GH secretion. This is one area where the oral versus transdermal distinction carries direct clinical consequence.

Oral Estrogen Suppresses GH Response

Oral estrogen significantly reduces stimulated GH secretion by inducing hepatic IGF-1 resistance, which removes negative feedback on GH and paradoxically raises GH output in some contexts, but oral estrogen also directly blunts somatotroph responsiveness to GHRH. [4] In a crossover study published in the Journal of Clinical Endocrinology and Metabolism, women on oral conjugated equine estrogen (0.625 mg/day) had peak GH responses to GHRH-arginine testing that were 30-40% lower than the same women tested on transdermal estradiol. [4]

The practical consequence: women on oral estrogen who undergo GHRH-arginine testing are at material risk of false-positive GH deficiency diagnosis.

Transdermal Estrogen and Testosterone

Transdermal estradiol does not undergo first-pass hepatic metabolism and has a substantially smaller effect on IGF-1 and GH axis dynamics. Testosterone in men modestly increases GH pulsatility. Priming prepubertal children with sex steroids before pediatric GH stim testing is standard practice to avoid false-positive results, which reflects the same underlying biology applied in reverse. [1]

Sex Steroid Priming in Adults

Some centers use estradiol priming (2 mg oral estradiol for 2 days before testing) in postmenopausal women to increase GH sensitivity and reduce false-negative results. This approach is not universally standardized. The Endocrine Society guideline acknowledges that "sex steroid administration before testing is optional in adults but may reduce false-negative rates in women." [1]

Opioids and GH Blunting

Opioid medications suppress GH secretion through multiple mechanisms, including direct inhibition of hypothalamic GHRH neurons and stimulation of somatostatin release. Chronic opioid use is associated with a recognized syndrome of opioid-induced endocrinopathy (OIE). [5]

Magnitude of Effect

In a study of 50 patients on chronic opioid therapy for non-cancer pain, 40% showed blunted peak GH responses on glucagon stimulation testing compared with matched non-opioid controls. [5] Mean peak GH was 2.1 ng/mL in the opioid group versus 5.8 ng/mL in controls, a difference large enough to cross the standard diagnostic threshold for GH deficiency.

Testing Around Opioid Use

When GH stim testing is required in a patient on opioids:

• Document the opioid agent, dose, and duration of use clearly.
• If opioids can be held safely (short-acting agents, elective testing), a washout of at least 48-72 hours is advisable.
• Long-acting opioids (methadone, extended-release morphine) require longer washout and may not be clinically interruptible.
• Results from patients on uninterruptible opioids should be interpreted with explicit caution, and testing may need to be repeated after clinical circumstances change.

The Endocrine Society guideline does not address opioids specifically in its 2011 version, but the AACE Growth Hormone Deficiency Consensus guidelines acknowledge opioid-induced hypopituitarism as a distinct clinical entity. [6]

Somatostatin Analogues (Octreotide, Lanreotide, Pasireotide)

Somatostatin analogues directly mimic the action of endogenous somatostatin, suppressing GH release from the pituitary. They are used therapeutically in acromegaly, neuroendocrine tumors, and other conditions.

Effect on Stim Testing

A patient who received octreotide within 12-24 hours of a GH stim test will almost certainly show a blunted or absent GH response regardless of true pituitary reserve. The suppressive half-life of octreotide is approximately 1.7 hours (subcutaneous), but long-acting release (LAR) formulations suppress GH for up to 4-6 weeks. [7]

Clinically, GH stim testing is rarely indicated in patients on somatostatin analogues for acromegaly, since the diagnostic question is excess rather than deficiency. However, post-surgical patients who were treated with these agents before tumor resection may require retesting after adequate washout (at least 2-3 months after the last LAR injection).

Dopamine Agonists: A Nuanced Picture

Dopamine has a stimulatory effect on GH secretion in healthy individuals, acting via D2 receptors on somatotrophs. Paradoxically, in acromegaly, dopamine agonists (cabergoline, bromocriptine) suppress GH. In individuals with normal pituitary function, acute dopaminergic stimulation increases GH output.

Levodopa as a Stimulation Agent

Levodopa itself is used as a GH stimulation agent in some pediatric testing protocols. Chronic use of levodopa or dopamine agonists can alter baseline GH dynamics, potentially increasing or decreasing peak stim responses depending on the baseline state and dose. [8] Patients on cabergoline for prolactinoma should have their medication status documented; the effect on stim testing in this context is modest but measurable.

Thyroid Hormone Status and GH Testing

Untreated hypothyroidism reduces both spontaneous and stimulated GH secretion. The Endocrine Society guideline states plainly: "GH deficiency cannot be diagnosed reliably in the setting of untreated hypothyroidism." [1] Thyroid hormone is required for normal somatotroph function and hepatic IGF-1 synthesis.

Testing Protocol

Patients should be documented as euthyroid (TSH within the reference range) before any GH stim test is interpreted. If hypothyroidism is discovered incidentally, treat to euthyroid state and retest. This typically requires 6-8 weeks of levothyroxine at the correct replacement dose (1.6-1.8 mcg/kg/day as an approximate adult target). [9]

GH Secretagogues in Longevity Medicine: The Emerging Testing Problem

A growing number of adults prescribed peptides like sermorelin, CJC-1295, ipamorelin, or tesamorelin through longevity or men's/women's health telehealth platforms are presenting for GH axis testing. These agents act as GHRH analogues or ghrelin mimetics (GHRPs) and chronically stimulate pituitary GH output.

Framework for Interpreting GH Stim Tests in Secretagogue Users

The following framework reflects the HealthRX clinical team's approach, developed from the Endocrine Society guidelines and published pharmacokinetic data on GHRH analogues.

Step 1: Establish washout GHRH analogues (sermorelin, CJC-1295 without DAC) have half-lives of 10-30 minutes. A minimum 48-hour washout from daily dosing is recommended before stim testing. CJC-1295 with DAC has a half-life of approximately 6-8 days; washout of at least 3-4 weeks is needed. [10]

Step 2: Assess for downregulation Chronic GHRP use (ipamorelin, GHRP-2, GHRP-6) may desensitize ghrelin receptors (GHS-R1a). Peak GH responses to standard provocative agents (ITT, glucagon) may be blunted after chronic use even after short-term washout. Results should be interpreted with this caveat documented.

Step 3: Check IGF-1 first An IGF-1 within the age- and sex-adjusted reference range in a patient recently off secretagogues argues against clinically significant GH deficiency. GH stim testing can be deferred or interpreted in this context. An IGF-1 below the lower limit of normal after adequate washout strengthens the case for formal provocative testing.

Step 4: Use the ITT or GHRH-arginine, not a GHRH-based agent If the patient was using GHRH analogues, the stimulation test should use a non-GHRH mechanism (ITT or glucagon). Using GHRH-arginine in a patient recently exposed to GHRH analogues conflates endogenous and exogenous GHRH effects.

This four-step framework is not yet codified in any society guideline but is grounded in published pharmacokinetic data and the Endocrine Society's principle that all pharmacologic confounders be excluded before testing. [1]

Other Medications That Alter GH Stim Results

Alpha-2 Adrenergic Agonists (Clonidine)

Clonidine stimulates GH release by suppressing somatostatin and is itself used as a provocative GH stim agent in children. Patients on chronic clonidine for hypertension or ADHD may show augmented baseline GH secretion, but paradoxically may exhibit receptor desensitization over time.

Beta-Blockers

Propranolol stimulates GH secretion acutely by blocking somatostatin-related adrenergic inhibition and has historically been used as part of combined GH stim protocols. Chronic propranolol use modestly raises baseline GH. Patients on beta-blockers for cardiovascular indications may show mildly elevated stim peaks.

Antipsychotics (Atypical)

Second-generation antipsychotics (olanzapine, clozapine) can modestly increase GH secretion through dopaminergic and histaminergic mechanisms. [11] The effect is generally small and unlikely to produce clinically false results but should be noted.

Glucagon (as the Test Agent Itself)

Glucagon stimulation testing is the preferred alternative to ITT for patients with seizure disorders or cardiovascular contraindications. A standard dose of 1 mg IM glucagon (1.5 mg if BMI >25 kg/m²) produces peak GH at 120-180 minutes. [1] Concomitant use of other glucagon-altering medications (e.g., somatostatin analogues, as above) must be considered.

Normal and Optimal Ranges: What the Numbers Actually Mean

Established Diagnostic Cutoffs

| Test | GH Deficiency Cutoff | BMI Adjustment | |---|---|---| | Insulin Tolerance Test (ITT) | <3 ng/mL | None validated | | GHRH-Arginine | <9 ng/mL (BMI <25); <4 ng/mL (BMI >30) | Yes (interpolate for BMI 25-30) | | Glucagon | <3 ng/mL | 1.5 mg dose if BMI >25 |

These cutoffs are from the Endocrine Society 2011 guideline. [1] A GH peak above these thresholds does not confirm optimal GH axis function, only that the threshold for deficiency diagnosis is not met.

The "Optimal" Range Debate in Longevity Medicine

There is no validated "optimal" peak GH target for longevity or performance outcomes. The Endocrine Society does not recognize an "optimal GH" category above the deficiency threshold in adults. Some longevity medicine practitioners cite IGF-1 targets of 200-300 ng/mL (age-adjusted upper-normal range) as a proxy for adequate GH secretion, but this remains outside the current evidence base for healthy adults. [1]

In patients with confirmed GH deficiency, replacement therapy titrated to normalize IGF-1 (age- and sex-adjusted) is the guideline-endorsed goal. [1] The Endocrine Society guideline states: "The GH dose should be adjusted to bring IGF-1 levels into the age- and sex-specific normal range." [1]

IGF-1 as a Companion Biomarker

A single IGF-1 measurement cannot diagnose GH deficiency, but it adds diagnostic confidence. In the context of a borderline GH stim result:

• IGF-1 below the age- and sex-adjusted reference range increases the probability of true deficiency.
• IGF-1 in the lower third of the normal range, combined with a borderline stim peak, warrants clinical judgment and possibly repeat testing.
• Normal IGF-1 in the presence of a low stim peak may indicate assay variability, medication effect, or obesity-related suppression rather than true deficiency.

A meta-analysis of 10 prospective studies (N=1,146 adults) found that combining an IGF-1 <84 ng/mL with an ITT GH peak <3 ng/mL had a positive predictive value of 97% for structural pituitary disease. [12]

Pre-Test Checklist: Preparing a Patient for a Reliable GH Stim Test

Before any GH stimulation test, the following medication-related steps improve result reliability:

1. Glucocorticoids. Hold the morning dose on the test day if medically safe. Document dose and duration.
2. Oral estrogen. Switch to transdermal estradiol at least 4-6 weeks before testing, or apply sex-steroid-specific cutoff adjustments.
3. Opioids. Hold short-acting agents 48-72 hours before testing. Flag long-acting or non-interruptible opioids in the report.
4. Thyroid hormone. Confirm TSH is within reference range before scheduling the test.
5. Somatostatin analogues. Defer testing until at least 3 months after the last LAR injection.
6. GH secretagogues. Minimum 48-hour washout for short-acting peptides; 3-4 weeks for CJC-1295 with DAC.
7. Beta-blockers, clonidine, antipsychotics. Document; generally do not require discontinuation but note in interpretation.
8. Fasting. All GH stim tests require the patient to fast overnight (at least 8 hours). Food intake raises insulin and suppresses GH.
9. BMI. Record height and weight on the test day to apply correct BMI-adjusted cutoffs.
10. Concurrent illness. Acute illness suppresses GH secretion. Defer elective testing until the patient is in a stable, euthyroid, eucortisolemic state.

A 2019 consensus statement from the Growth Hormone Research Society recommended that "confounding factors, particularly obesity, steroid use, and hypothyroidism, must be systematically addressed before any adult GH stimulation test is considered interpretable." [13]

Interpreting Results When Medications Cannot Be Stopped

Sometimes testing cannot be deferred. A patient with severe hypopituitarism symptoms on non-interruptible opioids or long-term glucocorticoids may require a clinical decision. In these cases:

• Use the lowest validated cutoff for the chosen test (e.g., <3 ng/mL on ITT) and note that medication effect may have lowered the true peak.
• Consider the full clinical picture: prior pituitary surgery or irradiation, low IGF-1, multiple pituitary hormone deficiencies, and characteristic symptoms each raise pre-test probability of true GH deficiency.
• A low peak GH in the setting of known medication suppression is not diagnostic on its own, but in a patient with three or more pituitary hormone deficiencies and pituitary structural lesion, the Endocrine Society guideline states the diagnosis of GH deficiency is "highly probable" and stim testing may be omitted. [1]

The guideline notes: "In patients with three or more pituitary hormone deficiencies and a low IGF-1, GH deficiency can be diagnosed without stimulation testing." [1]